Le Lézard
Classified in: Health, Science and technology
Subject: PER

Prometheus Biosciences Appoints Dr. Thierry Dervieux as Chief Development Officer


SAN DIEGO, Dec. 10, 2019 /PRNewswire/ -- Prometheus Biosciences, Inc., ("Prometheus") a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology (GI) and autoimmune diseases, announced today the appointment of Thierry Dervieux, PharmD, PhD, DABCC as chief development officer, diagnostics, and medical laboratory director. 

Prometheus Biosciences Logo (PRNewsfoto/Prometheus Biosciences, Inc.)

"Thierry's deep expertise in the development of innovative diagnostic assays and drug monitoring tools will benefit us greatly as we continue to advance our novel precision medicine platform for GI and autoimmune conditions," said Mark McKenna, chief executive officer of Prometheus Biosciences. "We are thrilled to welcome Thierry and we look forward to his contributions as we take Prometheus to the next level."

Dr. Dervieux joins Prometheus Biosciences from Exagen Diagnostics, a diagnostic company focused on chronic autoimmune diseases, where he served as chief scientific officer and medical director. Prior to joining Exagen, Dr. Dervieux was vice president of research and development at Cypress Bioscience, Inc. and senior director of research and development with Proprius Pharmaceuticals, Inc. (acquired by Cypress Bioscience, Inc.). Prior to that, he served as principal scientist and director of research and development at Prometheus Laboratories. Dr. Dervieux is board certified by the American Board of Clinical Chemistry and holds certificates of qualification as medical laboratory director in the categories of cellular immunology, clinical chemistry, drug monitoring, genetic testing, and diagnostic immunology. Dr. Dervieux holds PharmD and PhD degrees from Claude Bernard University in Lyon, France, an inter-university diploma in biostatistics from Pierre and Marie Curie University in Paris, France, and trained at St. Jude Children's Research Hospital in Memphis, Tennessee.

About Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

Prometheus Biosciences, Inc., created through the June 2019 acquisition of Prometheus Laboratories by Precision IBD, is headquartered in San Diego, California. For more information about Prometheus, please visit us at www.prometheusbiosciences.com.

Contacts:

Investor Relations and Media Contact
Juniper Point
Amy Conrad, (858) 914-1962
[email protected]

Connor Glenn, (858) 200-7888 
[email protected]

SOURCE Prometheus Biosciences, Inc.


These press releases may also interest you

at 09:20
Snowflake , the Data Cloud Company, today announced the general availability of Snowflake Data Clean Rooms to customers in AWS East, AWS West, and Azure West, revolutionizing how enterprises of all sizes can securely share data and collaborate in a...

at 09:20
TCP Software, a leader in time, attendance, and employee scheduling solutions, announced today an enhanced integration between two of their flagship platforms, TimeClock Plus and Humanity. The integration combines two leading solutions into one...

at 09:20
Jackson + Coker Locum Tenens, a leader in staffing solutions for locum tenens, today announced that it has been named a winner of Staffing Industry Analysts' (SIA) 2024 Best Staffing Firms to Work For award. Out of 400 firms that applied for...

at 09:20
RefleXion Medical, Inc., a therapeutic oncology company, and Limbus AI, Inc., a provider of software solutions for cancer radiation therapy, today announced a licensing agreement to incorporate Limbus' automated contouring software, Limbus Contour,...

at 09:15
UserTesting, a SaaS leader in experience research and insights, today announced customer TULA Skincare boosted conversion rates by 300 percent with the UserTesting® Human Insight Platform. The research and design teams at TULA benefited from the rich...

at 09:15
Identity Digitaltm, a leader in connecting the online world with domain names and related technologies, today announced its partnership with Invest.Green. Invest.Green democratizes green investing by bringing institutional quality insights and...



News published on and distributed by: